KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1. Participants will receive a conditioning regimen, KK-LC-1 TCR-T cells, and aldesleukin. The safety profile and clinical response to treatment will be determined.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Zaawansowany nowotwór stały (przerzutowy) z co najmniej 10% komórek raka wykazujących KK-LC-1
- •Posiadanie określonego markera HLA-A*01:01
- •Mierzalna choroba według standardowych kryteriów
- •Poprzednia standardowa chemioterapia lub udokumentowana przyczyna jej niemożliwości
- •Maksymalnie 3 przerzuty do mózgu, wcześniej leczone i stabilne
- •Dobra ogólna sprawność fizyczna (wg skali ECOG 0 lub 1)
- •Dla kobiet: negatywny test ciąży i stosowanie antykoncepcji przez 12 miesięcy
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 25, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
Rutgers Cancer Institute
New Brunswick, United States
RWJBarnabas Health - Robert Wood Johnson University Hospital
New Brunswick, United States
Trial contact
Tobi Adewale
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.